CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported results from two studies of VELCADE® (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM). The first study investigated the safety and efficacy of VELCADE in combination with LY2127399, a human monoclonal antibody. The second study assessed the safety and efficacy of VELCADE in combination with panobinostat. These data were presented at the annual meeting of the American Society of Clinical Oncology, held June 3 through 7 in Chicago, Illinois.
